Attached files
| file | filename |
|---|---|
| EX-99.01 - EXHIBIT 99.01 - Inspyr Therapeutics, Inc. | v335884_ex99-01.htm |
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): February 21, 2013 (February 21, 2013)
GENSPERA, INC.
(Exact name of registrant as specified in Charter)
| Delaware | 0001421204 | 20-0438951 | ||
|
(State or other jurisdiction of incorporation or organization) |
(Commission File No.) | (IRS Employee Identification No.) |
2511 N Loop 1604 W, Suite 204
San Antonio, TX 78258
(Address of Principal Executive Offices)
210-479-8112
(Issuer Telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On February 21, 2013, GenSpera, Inc. (the “Company”) announced that the first patient has been treated in the Phase II clinical trial of its lead compound, G-202, in patients who have hepatocellular carcinoma. A copy of the press release is attached to this report as Exhibit 99.01.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 21, 2013
| GenSpera, Inc. | |||
| By: |
/s/ Craig Dionne | ||
|
Craig Dionne | |||
| Chief Executive Officer | |||
INDEX OF EXHIBITS
| Incorporated by Reference | ||||||||||||
|
Exhibit No. |
Description |
Filed Herewith |
Form |
Exhibit No. |
File No. |
Filing Date | ||||||
| 99.01 | Press Release dated February 21, 2013 | * | ||||||||||